[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteo-arthritis-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteo-arthritis-knee":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,41,73,95,124,152,184,208,232,255,282,313,344,372,402,424,454,474,505,526,548,574,605,627,653],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100512709","characteristics-of-hoffa-adipose-tissue-and-intramuscular-adipose-tissue-in-the-quadriceps-muscle-100512709",false,"NCT05955976","Characteristics of Hoffa Adipose Tissue and Intramuscular Adipose Tissue in the Quadriceps Muscle","Study to Compare the Characteristics of Hoffa Adipose Tissue and Intramuscular Adipose Tissue in the Quadriceps Muscle","ADIPENIGME","Inclusion Criteria:\n\n* Adult patient, aged between 40 and 85 years\n* Patient having a confirmed diagnosis of knee ostheoarthritis\n* Patient undergoing a surgery for a total knee prosthesis for knee ostheoarthritis\n\nExclusion Criteria:\n\n\\-","ALL","40 Years","85 Years",{"count":22,"type":23},20,"ESTIMATED","OBSERVATIONAL","Over the last few years, it has been suggested that Knee Ostheoarthritis (KOA) incidence and progression could potentially be related to skeletal muscle characteristics. In particular, weakness of the quadriceps muscle would be a key determinant of KOA. However the mechanisms underpinning the influence of skeletal muscle in the pathophysiology of ostheoarthritis (OA) are poorly understood.\n\nCrosstalk between skeletal muscle and structures around and in the joint is of interest. In physical deconditioning and aging, it has been reported that skeletal muscle can be replaced by adipose tissue. Several factors involved in the development of OA but also of adipose tissue may be involved in these muscular changes. Of interest, in patients with KOA, quadriceps weakness is an ubiquitous clinical finding. Infiltration of adipose tissue in skeletal muscle has been shown to affect muscle strength and mobility and be linked to cartilage volume loss and the occurrence\u002Fprogression of KOA.\n\nThe main objective of this study is to compare the characteristics of the Hoffa tissus and the intamuscular fat (IMF) tissus in the quadriceps muscle in patients with gonarthrosis requiring total knee prosthesis.\n\nThis is a single-centre study based on a collection of surgical waste and is categorized as Research Not Involving Human subjects.",[27],"Osteo Arthritis Knee","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2023-07-20",{"date":36,"type":23},"2027-06-20",{"name":38,"class":39},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100504462","gait-rehabilitation-to-treat-fastoa-100504462","NCT05848622","Gait Rehabilitation to Treat FastOA","Inclusion Criteria:\n\n* Have completed all other formal physical therapy\n* Are between the ages of 16 and 35\n* Underwent an anterior cruciate ligament reconstruction (ACLR) between 6 and 60 months prior to enrollment\n* Demonstrate underloading during gait (vGRF- impact peak \\\u003C1.12 x BW)\n\nExclusion Criteria:\n\n* A multiple ligament surgery (i.e., PCL)\n* A lower extremity fracture (i.e., displaced tibial plateau fracture)\n* Knee osteoarthritis","16 Years","35 Years",{"count":50,"type":23},70,"INTERVENTIONAL",[53],"NA","The purpose of this study is to determine the effects of real-time gait biofeedback delivered over a 6-week period on early markers of FastOA and conduct 6-week and 6-month follow-up assessments in anterior cruciate ligament reconstructed patients.",[56,57,58,27,59,60,61],"Anterior Cruciate Ligament Injuries","Post-traumatic Osteoarthritis","Knee Osteoarthritis","Knee Injuries","Cartilage, Articular","Gait",[63,64],"Biofeedback","FastOA","2026-06-24",{"date":29,"type":32},{"date":68,"type":32},"2023-06-13",{"date":70,"type":23},"2027-06",{"name":72,"class":39},"University of North Carolina, Chapel Hill",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":51,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":40},"100520561","effects-of-home-base-whole-body-vibration-in-osteoarthritis-vibe-rx2-100520561","NCT06058169","Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2)","Pilot Investigation on the Effects of Sub Acute (12 Week) Home Base Whole-body Vibration Training in Osteoarthritis.","Inclusion Criteria:\n\n* Symptomatic Osteoarthritic knee pain for at least 6 months.\n* Mean and women\n* Ages 40-75 years old\n\nExclusion Criteria:\n\n* \\\u003C40 years old or \\>75 years old\n* History of balance issues\n* History of falls\n* Epilepsy\n* Pregnancy\n* The use of whole-body vibration in the past 6 months\n* Previous knee surgery within last 3 years\n* Unable to stand for at least 20 minutes (for whole body vibration training)","75 Years",{"count":5,"type":23},[53],"The purpose of this proposal is to understand how the Vibrant Health Ultimate whole-body vibration (WBV) machine affects pain and inflammation in older adults. The investigators' hypothesize that sub-acute (12 weeks) WBV will lead to improvement in the level of knee pain and improve vascular function via a decrease in systemic inflammation.",[85,27],"Whole Body Vibration","2026-05-12",{"date":88,"type":32},"2026-05-14",{"date":90,"type":32},"2025-04-25",{"date":92,"type":23},"2026-09-01",{"name":94,"class":39},"Augusta University",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":51,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100515479","use-of-a-putty-as-gap-filler-in-open-wedge-osteotomy-100515479","NCT05992038","Use of a Putty as Gap Filler in Open-wedge Osteotomy","A Randomized Controlled Trial of AttraX® Putty vs. Conventional Open-wedge Osteotomy Without Gap Filler in Open-wedge Osteotomy","AXOS","Inclusion Criteria:\n\n* indication for an open-wedge osteotomy of the femur, tibia or double level due to unicompartmental osteoarthritis (OA).\n* Comply with all aspects of the treatment, including CT scans, radiographs and 1-year follow-up\n* Informed consent\n\nExclusion Criteria:\n\n* Osteotomy for indication of cartilage treatment or other knee surgeries than unicompartmental OA\n* Correction using an open wedge above 10 mm\n* Pregnant women at time of enrollment or women who are planning to become pregnant during the duration of the study","18 Years",{"count":105,"type":23},40,[53],"Rationale: Realignment osteotomies around the knee are a proven surgical treatment for unicompartmental knee osteoarthritis and a malalignment. Osteotomies can be very painful in the early postoperative phase. This is probably due to a combination of bony cut (bone pain) and postoperative hematoma (bleeding and leakage of the bone marrow) in the surrounding soft tissue. The AttraX® Putty can be used as a gap filler in open wedge osteotomies to potentially reduce postoperative pain by reducing the bleeding from the bone gap.\n\nObjective: The main aim of this study is to determine whether early postoperative pain is decreased when the osteotomy gap is filled with AttraX® Putty, compared to conventional open wedge osteotomy without filling the gap. The secondary aims are faster accelerated rehabilitation\u002Fregaining function, reduction of local blood loss, accelerated bone union, comparable surgical accuracy, and the occurrence of (serious) adverse events.\n\nStudy design: Single-blinded, prospective, randomized controlled trial.\n\nStudy population: Adult patients qualifying for open-wedge tibial, open-wedge femur or double level osteotomy.\n\nIntervention: According to a randomization scheme, the osteotomy gap will be filled with either the synthetic ceramic material AttraX® Putty or without a gap filler (conventional method).\n\nMain study parameters\u002Fendpoints: The main study endpoint is the Numeric Rating Scale (NRS) pain during the first week postoperative. The secondary study endpoints are faster rehabilitation\u002Fregaining function, reduction of local blood loss, accelerated bone union, comparable surgical accuracy, and (serious) adverse events.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients may have the advantage of experiencing less pain postoperatively if they are treated with the AttraX® Putty, which can contribute to a faster rehabilitation. Risks to the AttraX® Putty group may include an allergic reaction, failure to promote bone fusion and excessive bone growth. However, the preclinical studies and clinical studies show that the use of AttraX® Putty is safe for use in humans.",[27],[110,111,112,113,114],"Osteotomy","Gap filler","Postoperative pain","Randomized controlled trial","AttraX Putty","2026-04-28",{"date":117,"type":32},"2026-04-29",{"date":119,"type":32},"2023-09-20",{"date":121,"type":23},"2026-12-01",{"name":123,"class":39},"UMC Utrecht",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":18,"minAge":103,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":51,"phases":135,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":40},"100630580","phase-4-arthrosamid-vs-steroid-for-the-management-of-knee-osteoarthritis-100630580","NCT07489521","Arthrosamid vs. Steroid for the Management of Knee Osteoarthritis","A Randomised Control Trial of the Use of an Intraarticular Hydrogel Arthrosamid® vs. Steroid for the Non-operative Management of Knee Osteoarthritis","Inclusion Criteria:\n\n* Adults\n* Symptomatic single side knee pain.\n* Patients with diagnosis of knee osteoarthritis radiographic Kellgren and Lawrence system OA grade II-III-IV on x ray or MRI.\n\nExclusion Criteria:\n\n* Inflammatory conditions,\n* Cancer,\n* acute infection,\n* pregnancy and breastfeeding.\n* Uncontrolled diabetes mellitus,\n* Joint diseases in the knee, such as rheumatoid arthritis or gout, history of knee surgery with metallic implant.\n* If patient has undergone knee arthroscopy in past 6 months.\n* Intra-articular injection of corticosteroids during the previous 3 months, intra-articular injection of other drugs, such as hyaluronic acid over the previous 1 year.\n* Contraindications for intra-articular injection, such as thrombocytopenia, coagulopathy, articular infection of knee, impairment of immunity.",true,"100 Years",{"count":134,"type":23},200,[136],"PHASE4","This study will be a randomised control trial of the use of intra-articular Arthrosamid® a novel intraarticular hydrogel vs. standard of care (steroid and local anaesthetic) for the non-operative management of knee osteoarthritis.",[27,139,140],"Osteoarthritis","Intraarticular Injection",[139,142,143],"knee","steroid injection","2026-04-23",{"date":115,"type":32},{"date":147,"type":32},"2026-01-29",{"date":149,"type":23},"2027-09",{"name":151,"class":39},"Cappagh National Orthopaedic Hospital",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":51,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":40},"100476677","the-impact-of-single-shot-adductor-canal-block-versus-continuous-femoral-nerve-block-on-rehabilitation-after-total-knee-replacement-100476677","NCT05487053","The Impact of Single-shot Adductor Canal Block Versus Continuous Femoral Nerve Block on Rehabilitation After Total Knee Replacement","The Impact of Single-shot Adductor Canal Block Versus Continuous Femoral Nerve Block on Rehabilitation After Total Knee Replacement (AdORe - ACB)","Inclusion Criteria:\n\n* Age ≥ 18\n* Planned primary total knee replacement\n* Planned neuraxial anesthesia\n* Written informed consent\n\nExclusion Criteria:\n\n* Urgent surgery\n* Planned revision total knee replacement\n* Known allergic reaction to anesthetics\n* Confirmed localized infection at the puncture sites\n* Confirmed localized tumor at the puncture sites\n* Peripheral neuropathy of the lower extremities\n* Parkinson's disease\n* Previously enrolled in this trial",{"count":160,"type":23},220,[53],"Total knee replacement (TKR) is considered the most effective and safe method of radical treatment of late stages of knee osteoarthritis. A well-known problem of TKR is a severe postoperative pain syndrome, which is observed in more than 50% of patients.\n\nFemoral nerve block (FNB) is the \"gold standard\" for continuous postoperative analgesia after total knee replacement, as it is effective in reducing the frequency of use of opioid analgetics and reduce the duration of hospitalization. At the same time, the negative effect of this method is the motor blockade of the quadriceps femoris muscle which leads to functional impairment and is associated with an increased risk of falling.\n\nAdductor canal block (ACB) provides adequate analgesia comparable to femoral nerve block. Moreover, ACB doesn't affect the motor function of the quadriceps femoris muscle.\n\nThe possibility of enhanced recovery after total knee replacement is the reason to compare single-shot adductor canal block and continuous femoral nerve block.",[27,164],"Gonarthrosis",[27,164,166,167,168,169,170,171,172,173],"Regional anesthesia","Analgesia","Postoperative analgesia","Total knee replacement","Continuous femoral nerve block","Femoral nerve block","Continuous adductor canal block","Adductor canal block","2026-04-10",{"date":176,"type":32},"2026-04-15",{"date":178,"type":32},"2024-02-03",{"date":180,"type":23},"2028-07-01",{"name":182,"class":183},"Negovsky Reanimatology Research Institute","OTHER_GOV",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":18,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":40},"100513519","rosa-knee-intraoperative-planning-flexibility-study-100513519","NCT05966519","ROSA Knee Intraoperative Planning Flexibility Study","ROSA Knee Intraoperative Planning Flexibility on Japan Preferred Surgical Technique, A Single Center Prospective Study","IntraOP","Inclusion Criteria:\n\n* 20 years and over\n* Skeletally matured\n* Decision to have Total Knee Arthroplasty with ROSA Knee System being made independently and prior to recruitment into study\n* Willing and able to complete scheduled follow-up evaluations as described in the study protocol\n* Has participated in the informed consent process and is willing and able to sign an Institutional Review Board (IRB)\u002FEthics Committee (EC) approved informed consent form\n\nExclusion Criteria:\n\n* Has serious bone defect(s), which require(s) metallic augment, synthetic bone or allograft\n* Is septic, has an active infection or has osteomyelitis at the affected joint\n* Has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which might jeopardize the outcome of the surgery\n* Has any concomitant disease which is likely to jeopardize the functioning or success of the implant\n* Is known to be pregnant\n* Is a prisoner, known alcohol or drug abuser or mentally incompetent or unable to understand what participation in this study entails\n* Has a known sensitivity or allergy to one or more of the implanted materials","20 Years",{"count":194,"type":23},80,"The purpose of this study is to verify that an orthopedic surgical assist robot (ROSA Knee System) can provide intraoperative adjustment of osteotomy angle and volume for total knee arthroplasty (TKA) based on feedbacks obtained from intraoperative soft tissue conditions. A total 80 cases will be enrolled at one study site with a postoperative follow-up period of 2 years.",[27,197],"Rheumatoid Arthritis","2026-04-02",{"date":200,"type":32},"2026-04-08",{"date":202,"type":32},"2024-01-05",{"date":204,"type":23},"2029-01",{"name":206,"class":207},"Zimmer Biomet","INDUSTRY",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":51,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100525219","misha-post-market-clinical-study-100525219","NCT06118892","MISHA Post-Market Clinical Study","Post-Market Evaluation of the MISHA® Knee System for Symptom Relief in Subjects With Medial Knee Osteoarthritis","Key Inclusion Criteria:\n\n1. Subjects aged 25 to 65 years at time of index procedure\n2. Body Mass Index (BMI) of \\\u003C 35\n3. Activity exacerbated knee pain isolated to the medial compartment and not global in nature\n4. WOMAC pain ≥ 40\n5. Failed non-operative OA treatment\n\nKey Exclusion Criteria:\n\n1. Large medial osteophyte(s) or considerable extruded meniscus that may interfere with the placement or function of the device\n2. Poor bone quality (e.g., bony erosion, osteopenia, osteoporosis)\n3. Ligamentous instability\n4. Active or recent knee infection\n5. Inflammatory joint disease, including sequalae of viral infections\n6. Suspected or documented allergy or hypersensitivity to cobalt, chromium, nickel or other metals\n7. History of keloid, hypertrophic or contracture scaring\n8. Propensity for restrictive scar formation or adhesions with prior procedures","25 Years","65 Years",{"count":218,"type":23},120,[53],"Prospective evaluation of the safety and effectiveness of the MISHA Knee System.\n\nThe study will collect data on the procedural and long-term adverse events, WOMAC pain and function scores, KSS satisfaction, subsequent surgical interventions, BMI levels, range of motion, UCLA activity level of the subjects, and perform radiographic\u002Fx-ray evaluations at clinical visits through 5 years post-procedure.\n\nThe primary analysis of this study is freedom from device- and procedure-related SSIs at five (5) years post-implantation.\n\nThis study will also assess device performance in subjects with intact and retained devices and subjects with devices removed prior to study termination and freedom from conversion to arthroplasty through 5 years.\n\nStudy subjects will be followed over a five-year post-implant period.",[27],"2026-03-31",{"date":224,"type":32},"2026-04-01",{"date":226,"type":32},"2023-11-03",{"date":228,"type":23},"2030-07-30",{"name":230,"class":207},"Moximed",3,{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":51,"phases":242,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":40},"100533894","phase-3-metformin-safety-and-efficacy-in-osteoarthritis-100533894","NCT06231758","Metformin Safety and Efficacy in Osteoarthritis.","The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n* Primary osteoarthritis Patients recruited were between 30 to 60 years of age.\n* X-ray confirmed Kellgren-Lawrence grade II or III severity primary tibiofemoral OA according to the American College of Rheumatology criteria.\n\nExclusion Criteria:\n\nPatients with age less than 30 years or more than 60 years Patients Presented with active concomitant gastroduodenal disorders, hepatic and renal impairment within last 30 days prior to receiving the study drug Patients Were diagnosed to have any inflammatory arthritis, gout or acute trauma of the knee, hip or spine; accompanying OA of the hip of sufficient severity to interfere with the functional assessment of the knee Patients had previous or ongoing treatment with oral SYSDOA (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics; were having active cardiac lesion or hypertension, were pregnant females and those who were planning their pregnancy during the study Patients having a known hypersensitivity to the used medications Patients have persistent diarrhoea or laxative use; severe gastrointestinal disorders, severe obesity, severe parenchymal organ disease, or anaemia (haemoglobin\\\u003C 10.0 g\u002F dl or haematocrit \\\u003C 30%).\n\nPatients who received oral, intramuscular, intraarticular or soft tissue injections of corticosteroids within last eight weeks before receiving the first dose of the study medication or had undergone joint lavage and arthroscopic procedures in the previous 6 months, were also excluded.","30 Years","60 Years",{"count":50,"type":23},[243],"PHASE3","Knee osteoarthritis (OA) is a chronic, painful disease associated with considerable morbidity, costs and disability. It is estimated that over a third of people aged over 60 have radiographic knee OA2 and over 50% of these with knee OA will go on to have a total knee replacement in their lifetime. At present there are no licensed treatments that alter disease progress and management is primarily concerned with symptom control to retain or improve joint function, although a trial of strontium ranelate showed promising results.",[27],"2026-03-12",{"date":248,"type":32},"2026-03-13",{"date":250,"type":32},"2024-01-30",{"date":252,"type":23},"2027-11-20",{"name":254,"class":39},"Mostafa Bahaa",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":131,"sex":18,"minAge":261,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":51,"phases":265,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":272,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":40},"100569993","measurement-of-osteoarthritic-patient-pain-through-electrodermal-activity-signals-100569993","NCT06701461","Measurement of Osteoarthritic Patient Pain Through Electrodermal Activity Signals","Study subjects\n\nInclusion Criteria:\n\n* Kellgren-Lawrence Grade \\>= 3\n\nExclusion Criteria:\n\n* Inflammatory arthropathy (e.g., rheumatoid arthritis), BMI \\>=35\n\nControl subjects:\n\nExclusion Criteria:\n\n* Complaints of lower extremity joint pain\n* Known diagnosis of knee osteoarthpathy\n* Prior history of knee surgery, knee injections, or injury to knee joints (e.g., meniscus tears, ligamentous injuries), BMI \\>=35\n\nBoth groups, exclusion:\n\n* Subjects with chronic heart problems, including, but not limited to, chronic hypertension, heart palpitations, a weak or irregular heartbeat, or a previous heart attack,\n* Subjects taking the following drugs within 12 hours of the experiment or during the experiment: caffeine, alcohol, psychoactive drugs, nicotine or marijuana, other recreational drugs, and medicine of any kind that is not normally taken daily. Such medications include;\n\n  * NSAIDs\n  * Acetaminophen\n  * Steroidal anti-inflammatory agents\n  * Bronchodilators\n  * Appetite suppressants\n  * Lipase inhibitors\n* Women who are currently pregnant\n* Subjects with Raynaud's syndrome\n* Subjects with any of the following conditions: active skin lesions where EDA sensors are, vertigo or dizziness, and anyone with postural orthostatic tachycardia syndrome (POTS), peripheral neuropathy, seizure disorders, methicillin-resistant staphylococcus aureus (MRSA), impaired circulation, medical implants, open skin lesions, chronic eczema on hands where EDA and electrical stimulator's electrodes are attached, diabetes, and epilepsy.\n* Participants who have a skin sensitivity to metals, have a pacemaker or defibrillator, or have recent head trauma within the past two weeks (even without loss of consciousness)\n* Participants who cannot feel physical pain or have a history of self-harm","50 Years","80 Years",{"count":264,"type":23},15,[53],"This pilot study aims to investigate the viability of using a smartwatch-based electrodermal activity (EDA) sensor to capture enough EDA signal to quantitatively assess pain in osteoarthritis subjects and test the feasibility of its methods and procedures for later use in subsequent larger-scale studies.",[27],[269,270,139,271],"Pain","Electrodermal Activity Signals","Knee","NOT_YET_RECRUITING","2026-03-04",{"date":275,"type":32},"2026-03-06",{"date":277,"type":23},"2026-08",{"date":279,"type":23},"2026-10",{"name":281,"class":39},"Dartmouth-Hitchcock Medical Center",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":18,"minAge":261,"maxAge":80,"enrollmentInfo":290,"targetDuration":4,"studyType":51,"phases":292,"briefSummary":293,"conditions":294,"keywords":297,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":40},"100461604","total-versus-robotic-assisted-unicompartmental-knee-replacement-100461604","NCT05290818","Total Versus Robotic Assisted Unicompartmental Knee Replacement","Total Versus Robotic Assisted Unicompartmental Knee Replacement (TRAKER) for Medial Compartment Osteoarthritis: Randomised Controlled Trial","TRAKER","Inclusion Criteria:\n\n* Listed for elective primary TKA for end stage medial compartment osteoarthritis\n* Intact anterior cruciate ligament\n* Full thickness and good quality lateral cartilage\n* Correctable intra-articular varus deformity and intact medial collateral ligament\n* American Society of Anesthesiologists (ASA) grades 1 and 2\n* Male or female, age 50 - 75 at the time of listing for surgery\n* Suitable candidate for a cruciate retaining TKA (Triathlon prosthesis) and a UKA\n\nExclusion Criteria:\n\n* Varus deformity of \\> 20 degrees\n* Fixed flexion of \\>10 degrees\n* Patient is unable to comply with the study protocol (incl. refusal for CT scan) or functional assessments\n* Female participants who are pregnant, lactating or planning pregnancy during the course of the study\n* Requires patella resurfacing or lateral compartment has significant OA\n* Inability to understand the patient information for the study, provide written informed consent or answer study questionnaires for cognitive or language reasons\n* Inflammatory disorder e.g. rheumatoid arthritis\n* Symptomatic foot, hip or spine pathology\n* Prior surgery (other than arthroscopy) or septic arthritis of the knee\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study,",{"count":291,"type":23},159,[53],"The purpose of this research is to compare the functional outcomes of patients with end stage medial compartment OA of the knee undergoing a conventional mTKA to those undergoing rUKA and to assess the associated cost economics of such technology.",[27,295,296],"Arthritis Knee","Arthropathy of Knee",[298,299,271,300,301,302,303],"Arthroplasty","Robotic","Total","Partial","Outcome","MAKO","2026-02-04",{"date":306,"type":32},"2026-02-06",{"date":308,"type":32},"2024-08-26",{"date":310,"type":23},"2027-12-31",{"name":312,"class":183},"NHS Lothian",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":80,"enrollmentInfo":320,"targetDuration":4,"studyType":51,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":343},"100568737","combined-use-of-prp-and-hyaluronic-acid-for-infiltrative-treatment-of-patients-with-knee-osteoarthritis-100568737","NCT06685120","Combined Use of PRP and Hyaluronic Acid for Infiltrative Treatment of Patients With Knee Osteoarthritis","Combined Use of PRP and Hyaluronic Acid for Infiltrative Treatment of Patients With Knee Osteoarthritis - Randomized Controlled Clinical Study","Inclusion Criteria:\n\n1. Male or female patients, aged 40 to 75 years;\n2. Patients with symptomatic knee osteoarthritis (VAS pain score between ≥ 3 and ≤ 8);\n3. Unilateral involvement of symptomatology;\n4. Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3);\n5. Failure, defined as the persistence of symptomatology, after at least one course of conservative treatment (pharmacological, physiotherapeutic or infiltrative treatment);\n6. Hemoglobin \\> 11 g\u002Fdl; Platelet count \\> 150,000 plt\u002Fmm3 (Recently performed CBC examination);\n7. Ability and consent of patients to actively participate in clinical follow-up;\n8. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Patients unable to express consent;\n2. Patients undergoing intra-articular infiltration of other substance in the previous 6 months;\n3. Patients undergoing knee surgery in the previous 12 months;\n4. Patients with malignant neoplasms;\n5. Patients with rheumatic diseases;\n6. Patients with uncontrolled diabetes;\n7. Patients with hematological diseases (coagulopathies);\n8. Patients on anticoagulant-antiaggregant therapy that cannot be discontinued at the time of blood collection;\n9. Patients with uncompensated thyroid metabolic disorders;\n10. Patients abusing alcoholic beverages, drugs or medications;\n11. Body Mass Index \\> 35;\n12. Patients who have taken NSAIDs in the 3 days prior to blood draw;\n13. Patients with cardiovascular disease for whom blood sampling 30 to 60 ml would be contraindicated;\n14. Patients with recently performed CBC examination with Hb\\\u003C 11 g\u002Fdl and Platelet values \\\u003C 150,000 plt\u002Fmm3.\n15. Pregnant and\u002For fertile women.",{"count":321,"type":23},288,[53],"\"PRP+HA-23\" is a double-blind randomized controlled clinical trial with 1:1:1 allocation. The objective of the study is to evaluate by a randomized controlled, double-blind clinical trial the efficacy and safety of viscosupplementation-associated PRP infiltration compared with PRP-only or HA-only infiltration for the treatment of patients with knee osteoarthritis.",[27],[326,327,328,329,330,331,332,333],"PRP","Platelet rich plasma","HA","Hyaluronic acid","PRP injection","PRP + HA injection","HA injection","Double-blind randomized controlled clinical trial","2026-01-30",{"date":336,"type":32},"2026-02-03",{"date":338,"type":32},"2025-12-11",{"date":340,"type":23},"2029-09",{"name":342,"class":39},"Istituto Ortopedico Rizzoli",2,{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":240,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":51,"phases":352,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":40},"100545697","phase-1-the-role-of-vitamin-k-on-knee-osteoarthritis-outcomes-100545697","NCT06385275","The Role of Vitamin K on Knee Osteoarthritis Outcomes","Inclusion Criteria:\n\n* ≥60 years old\n* Clinical diagnosis of knee OA by the treating rheumatologist\n* English fluency\n\nExclusion Criteria:\n\n* Anticoagulation use (including warfarin, dabigatran, rivaroxaban, apixaban)",{"count":351,"type":23},55,[353,354],"PHASE1","PHASE2","The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known,\n\nThe overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures.",[27],[358,359,360,361,362],"Vitamin K-1","Vitamin K-2","Menaquinone-7 (MK-7)","Uncarboxylated matrix Gla protein (ucMGP)","Phylloquinone","2026-01-21",{"date":365,"type":32},"2026-01-23",{"date":367,"type":32},"2025-06-03",{"date":369,"type":23},"2026-12",{"name":371,"class":39},"Boston University",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":379,"minAge":240,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":51,"phases":382,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":40},"100488603","effects-of-fall-prevention-program-on-the-number-of-falls-among-elderly-following-total-knee-replacement-100488603","NCT05642260","Effects of Fall Prevention Program on the Number of Falls Among Elderly Following Total Knee Replacement","The Short- and Long-term Effects of Fall Prevention Program on the Number of Falls Among Elderly Following Total Knee Replacement: a Pragmatic Single-blinded Randomized Controlled Trial.","Inclusion Criteria:\n\n* Female gender.\n* Aged 60 years and older.\n* Diagnosed with primary osteoarthritis of the knee.\n* Underwent unilateral TKR.\n\nExclusion Criteria:\n\n* revision TKR surgery\n* history of systemic inflammatory conditions (i.e., rheumatoid arthritis, Lupus erythematosus),\n* neurological disorders (i.e., multiple sclerosis, Parkinson's disease, stroke)\n* lower limb surgery\u002Ftrauma in the past 12 months\n* have cognitive and\u002For vision impairments\n* post-surgical complications (e.g., infection, intraoperative fracture)\n* any health condition that may preclude them from undertaking physiotherapy.","FEMALE",{"count":381,"type":23},90,[53],"the aim of the proposed research is to investigate the short and long-term effects of integrating a comprehensive fall prevention programme into conventional physiotherapy on the number of falls, balance, and functional ability among elderly following TKR. the investigator hypothesize that conventional physiotherapy integrated with a fall prevention program is more effective than conventional physiotherapy alone in improving balance and functional ability and preventing the occurrence of falls among elderly following TKR.\n\nStudy type: The proposed study is a parallel group prospective (24 weeks) randomised single-blinded pragmatic controlled trial.\n\nParticipants: Older adults operated for TKR at Al-Razi orthopedic hospital, who met the inclusion criteria.",[385,27,386],"Fall","Total Knee Replacement",[388,389,390,391,392],"fall","older people","fall prevention","TKR","rehabilitation","2025-12-02",{"date":395,"type":32},"2025-12-09",{"date":397,"type":32},"2023-01-08",{"date":399,"type":23},"2026-09-08",{"name":401,"class":183},"Ministry of Health, Kuwait",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":80,"enrollmentInfo":410,"targetDuration":4,"studyType":51,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":40},"100553419","phase-2-an-study-to-evaluate-safety-and-tolerability-of-oa-sys-in-subjects-with-moderate-to-severe-osteoarthritis-of-the-knee-joint-100553419","NCT06485843","An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint","An Open Label Phase IIb Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint","OA-SYS-01","Inclusion Criteria:\n\n* Adults between the ages of 35 - 75 years Body Mass Index (BMI) less than 39 kg\u002Fm2\n* Ambulatory and in good general health\n* Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions\n* Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Treatment\n* Kellgren-Lawrence grading scale score of 3 or 4 for OA of the knee\n* No clinically significant abnormalities observed in medical history, physical exam vital signs, and laboratory assessments\n* For females of reproductive potential: use of effective contraception for at least 1 month prior to screening and agreement to use such a method till end of the study period and negative pregnancy test\n* For males of reproductive potential: use of condoms and other methods to ensure effective contraception\n\nExclusion Criteria:\n\n* Known or suspected infection of the target joint\n* Subjects with surgery for OA in the target joint\n* Subject with reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease\n* Subject with myocardial infarction, congestive heart failure, and other severe heart disease or hypertension (or medical history of hypertension) that are not controlled below 140\u002F90 mmHg even with treatment with more than three antihypertensive drugs\n* Subject with serious medical conditions other than cardiovascular disease\n* Subject with, or with a medical history of autoimmune diseases\n* Subject with an infection that requires parenteral antibiotic administration within 30 days prior to screening\n* Subject with a medical history of mental disorder or epilepsy\n* Subject abuse alcohol 10 times a week or smoke 25 cigarettes a day\n* Subject who was diagnosed with cancer within 5 years before screening\n* Subject who participated in another clinical trial within 6 months prior to the screening of this clinical trial\n* Subject who was administered with immunosuppressants such as cyclosporin A or azathioprine within 6 weeks prior to the screening\n* Subject who had intra-articular administration such as sodium hyaluronate injections within 6 months prior to the screening\n* Clinical findings consistent with active infection or crystal disease in the index joint within 1 month prior to the screening\n* History of fracture in the index limb or fracture with sequelae within 12 months prior to the screening\n* Joint instability or history of acute dislocation within 12 months prior to the screening\n* Planned or anticipated surgery of the joint during the study period\n* Presence of surgical hardware or other foreign body in the index joint\n* Surgery or arthroscopy of the index joint within 12 months of screening\n* Intra-articular treatment of any joint with any of the following agents within 6 months prior to the screening: Any corticosteroid preparation (investigational or marketed), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection)\n* Treatment of the index joint with any investigational therapy within 6 months prior to the screening\n* Serious life-threatening conditions\n* Allergies to anesthesia\n* Subject who is breastfeeding.",{"count":411,"type":23},400,[354],"This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.",[139,27],"2025-09-12",{"date":417,"type":32},"2025-09-18",{"date":419,"type":32},"2025-05-21",{"date":421,"type":23},"2028-12-31",{"name":423,"class":207},"Ageless Biotech, Inc.",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":131,"sex":18,"minAge":19,"maxAge":262,"enrollmentInfo":431,"targetDuration":4,"studyType":51,"phases":433,"briefSummary":434,"conditions":435,"keywords":438,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":40},"100369845","rct-mako-medial-unicondylar-knee-arthroplasty-vs-oxford-unicondylar-knee-arthroplasty-100369845","NCT04095637","RCT: Mako Medial Unicondylar Knee Arthroplasty vs Oxford Unicondylar Knee Arthroplasty","A Prospective Randomised Control Trial of Mako Medial Unicondylar Knee Arthroplasty Versus Jig-based Oxford Unicompartmental Knee Arthroplasty With Navigation Contro","Inclusion Criteria:\n\n* • Patient has medial unicompartmental knee osteoarthritis requiring primary UKA\n\n  * Patient and Surgeon are in agreement that UKA is the most appropriate treatment\n  * Patient is fit for surgical intervention following review by surgeon and anaesthetist\n  * Patient is between 40-80 years of age at time of surgery\n  * Gender: male and female\n  * Patient must be capable of giving informed consent and agree to comply with the postoperative review program\n  * Patient must be a permanent resident in an area accessible to the study site\n  * Patient must have sufficient postoperative mobility to attend follow-up clinics and allow for radiographs to be taken\n\nExclusion Criteria:\n\n* • Patient is not suitable for primary UKA e.g. multi-compartmental knee osteoarthritis, anterior cruciate ligament rupture\n\n  * Patient is not medically fit for surgical intervention\n  * Patient requires revision surgery following previously failed correctional osteotomy or ipsilateral UKA\n  * Patient is immobile or has another neurological condition affecting musculoskeletal function\n  * Patient is less than 40 years of age or greater than 80 years of age\n  * Patient is already enrolled on another concurrent clinical trial\n  * Patient is unable or unwilling to sign the informed consent form specific to this study\n  * Patient is unable to attend the follow-up programme\n  * Patient is non-resident in local area or expected to leave the catchment area postoperatively",{"count":432,"type":23},140,[53],"The overall aim of this prospective, randomised, single-blinded, controlled trial is to compare clinical outcomes and accuracy of implant positioning in Mako robotic UKA versus jig-based Oxford UKA with navigation control. Patients receiving the Mako robotic UKA (Stryker Ltd) will form the investigation group and those undergoing the jig-based Oxford UKA (Zimmer-Biomet Ltd) with navigation control will form the control group.\n\nThe primary objective in this study is to compare accuracy of component positioning as assessed by postoperative low radiation dose CT scan between conventional Jig-based Oxford UKA with navigation control and Mako robotic UKA.",[436,27,437],"Unicompartmental Knee Replacement","Surgery",[439,440,441,442,443,444],"alignment","computer navigation","implant position","mako robot","makoplasty","unicondylar knee replacement","2025-07-07",{"date":447,"type":32},"2025-07-09",{"date":449,"type":32},"2017-11-24",{"date":451,"type":23},"2026-01-01",{"name":453,"class":39},"University College, London",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":240,"maxAge":262,"enrollmentInfo":461,"targetDuration":4,"studyType":51,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":472,"locationsCount":343},"100526147","the-effect-of-a-2-week-preoperative-vegan-diet-versus-omnivorous-diet-on-the-protein-turnover-in-the-osteoarthritic-knee-100526147","NCT06130956","The Effect of a 2-week Preoperative Vegan Diet Versus Omnivorous Diet on the Protein Turnover in the Osteoarthritic Knee","KneeT-vegan","Inclusion Criteria:\n\n* Written informed consent;\n* Patients scheduled for total knee arthroplasty;\n* BMI between 20-32 kg\u002Fm2;\n* Aged 60 - 80 years;\n* Mentally competent, as judged by the treating physician;\n\nExclusion Criteria:\n\n* Following a vegetarian or vegan diet or a diet that affects protein intake during the six months prior to the study;\n* Participating in a structured progressive exercise training program in the past three months;\n* Lost more than 4 kg body weight during three months prior to the study;\n* Chronic use of medications that affect protein metabolism (i.e. systemic corticosteroids, or prescription strength acne medications);\n* Being diagnosed with one of the following: diabetes mellitus, rheumatoid arthritis, peripheral artery disease Fontaine III or IV, COPD GOLD III or IV, neoadjuvant chemotherapy or radiotherapy, phenylketonuria, collagen disorders (e.g. Marfan and Ehler-Danlos);\n* Alcohol abuse;\n* Surgical intervention to the knee in the past four weeks;\n* Total parenteral nutrition at day of surgery;\n* Glomerular filtration rate (GFR) \\\u003C20 mL\u002Fmin\u002F1.73 m2;\n* Allergic or intolerant to any product included in the diets;\n* Osteoarthritis of the knee secondary to septic arthritis, osteonecrosis, fracture, osteochondritis dissecans, or malignant processes;\n* Any other medical condition that may interfere with the safety of the participants or the outcome parameters, in the investigators judgement;\n* Not willing to stop nutritional supplements, with the exception of vitamin D and supplements on medical advice.\n* Investigator's uncertainty about the willingness or ability of the participant to comply with the protocol instructions;\n* Participation in other studies that may have an impact on the outcomes during the three months before the start of the current study.",{"count":105,"type":23},[53],"Rationale: Protein from plant-based foods may be unable to stimulate protein synthesis due to a suboptimal essential amino acid content and a lower digestibility. However, a more optimal amino acid profile may be achieved by increasing portions sizes and blending multiple plant-based sources. Studies investigating the anabolic properties of vegan diets (total elimination of animal-based foods) rather than single plant-based foods in older adults are scarce. It remains unknown if a vegan diet can also affect protein synthesis rates in other musculoskeletal tissues than muscle.\n\nPrimary objective: To assess the effects of a 2-week preoperative vegan diet in comparison to an omnivorous diet on protein synthesis rates in Hoffa's fat pad, synovium, tendon, bone, ligaments, menisci, and cartilage in older adults with knee osteoarthritis undergoing total knee arthroplasty.\n\nSecondary objective: To assess the effects of a 2-week preoperative vegan diet in comparison to an omnivorous diet on blood pressure and plasma amino acids in older adults with knee osteoarthritis undergoing total knee arthroplasty.\n\nStudy design: Multi-center, randomized, controlled trial with an intervention and a control group.\n\nStudy population: 40 older adults (60 - 80 years) with osteoarthritis of the knee undergoing total knee replacement.\n\nIntervention: Controlled vegan diet versus controlled omnivorous diet, for a duration of 14 days.\n\nMain study parameters\u002Fendpoints: Primary study parameters are protein synthesis rates of Hoffa's fat pad, synovium, tendon, bone, ligament, menisci, and cartilage. Secondary parameters include blood pressure and plasma amino acids.",[27,465],"Protein Synthesis","2025-03-25",{"date":468,"type":32},"2025-04-01",{"date":470,"type":32},"2024-10-22",{"date":369,"type":23},{"name":473,"class":39},"Wageningen University",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":240,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":51,"phases":481,"briefSummary":482,"conditions":483,"keywords":489,"overallStatus":272,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":40},"100536402","developing-a-nonpharmacological-pain-intervention-for-community-dwelling-older-adults-with-dementia-100536402","NCT06264362","Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia","Inclusion Criteria for people living with dementia:\n\n* Age 60 or older\n* Speaks English\n* Mild\u002FVery Mild dementia\n* Knee pain lasting ≥ 3 months, potentially related to arthritis\n* Knee pain is at least 2 out of 10 on average.\n\nExclusion Criteria for people living with dementia:\n\n* Reside in long term care facility\n* Unable or unwilling to consent\n* Has a condition with a life expectancy of less than 1-year\n* No care partner who is also willing to participate\n* Recent changes to pain or psychotropic medications in the last 60 days\n* Recent knee surgery in the last 1-year\n* Has a condition that contraindicates exercise (Phase 2 only)\n* Currently receiving rehab services (Phase 2 only)\n\nFor care partners:\n\n* No sex, gender, or age criteria\n* Has known person living with dementia ≥ 1 year\n* Speaks English\n* Able and willing to consent, including being recorded\n\nFor clinicians:\n\n* No sex, gender, or age criteria\n* Speaks English\n* Has ≥ 2 years of experience working with community-dwelling people with dementia and pain\n* Able and willing to consent, including being recorded",{"count":105,"type":23},[53],"The purpose of this study is to develop an exercise treatment program for knee osteoarthritis that works well for people with memory problems. This study will include two parts. Participants can choose to participate in either or both parts.\n\nIn Part 1 (not a clinical trial) - The investigators are inviting the following people to participate in an interview:\n\n1. Individuals aged 60 years or older who do not live in a nursing home and have both memory issues and knee pain.\n2. Care partners of people with knee pain and memory issues. A care partner can be a family member or friend who helps regularly.\n3. Clinicians (exercise physiologists or rehabilitation therapists like physical and occupational therapists) who have worked with older adults with memory issues and knee pain.\n\nThe goal of these interviews is to learn from the experiences of people with memory issues and knee pain and those who care for them. From these interviews, the investigators hope to design a non-drug, tailored physical activity program that will be interesting and helpful in managing knee pain for older adults with memory problems.\n\nFor people with memory problems and knee pain and their care partners: The investigators will ask some questions to determine eligibility to participate in the study.\n\nThose who qualify for the study will be invited to participate in an interview that could be completed online or in person (Philadelphia, PA). The interview could last up to 90 minutes (1 and a half hours) and can be completed as one or multiple sessions.\n\nFor clinicians: Participants will engage in a 90-minute focus group with other clinicians where lunch will be served if in person. Those participating in an online focus group will receive a gift card equal to the value of lunch.\n\nIn Part 2 (a clinical trial) - The program developed in Part 1 will be tested. The program will be physical activity-based. Specific program details for part 2 will be provided as they emerge. Participants can choose to sign up for either or both parts. Signing up for Part 1 does not mean participants have to sign up for Part 2.\n\nPlease contact us for any questions.",[484,485,486,487,27,488],"Pain, Chronic","Dementia, Mild","Mobility Limitation","Physical Disability","Mild Cognitive Impairment",[490,491,492,493,494,495],"pain","dementia","cognitive impairment","osteoarthritis","knee pain","memory","2025-03-10",{"date":498,"type":32},"2025-03-11",{"date":500,"type":23},"2025-06-02",{"date":502,"type":23},"2027-05-01",{"name":504,"class":39},"Drexel University",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":511,"maxAge":262,"enrollmentInfo":512,"targetDuration":4,"studyType":51,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":40},"100307791","balancing-kinematically-aligned-total-knee-replacements-during-total-primary-knee-arthroplasty-using-verasense-100307791","NCT03286868","Balancing Kinematically Aligned Total Knee Replacements During Total Primary Knee Arthroplasty Using Verasense","Inclusion Criteria:\n\n* Symptomatic arthritis of the knee indicating primary total knee arthroplasty\n* Between the ages of 21 and 80 inclusive\n* Patients willing and able to comply with follow-up requirements and self-evaluations\n* Ability to give informed consent\n* Varus alignment\n\nExclusion Criteria:\n\n* Patients less than 21 years of age, or 81 years of age and older\n* Unable to provide consent\n* BMI \\>45\n* Pregnancy\n* Patients with inflammatory arthritis, posttraumatic osteoarthritis, post high tibial osteotomy, or arthritis due to sepsis will be excluded.\n* Active or prior infection\n* Medical condition precluding major surgery\n* Severe osteoporosis or osteopenia\n* Neuromuscular impairment\n* Significant co-morbidity affecting ability to ambulate\n* Valgus alignment","21 Years",{"count":513,"type":23},60,[53],"Total Knee Replacement (TKR) is an operation to help with the pain and decreased function that happens with end stage arthritis of the knee. This operation has been shown to be very successful at relieving pain and improving patient mobility; however, some studies have shown that up to 20% of TKR recipients are not happy with their knee replacement.\n\nAll of the reasons why some patients are not pleased with the outcome of surgery are not known, but one of the possible causes is the way the implants are placed, or aligned, during surgery. Most TKRs are aligned in a fashion that the bones in the leg are completely straight after surgery. This is known as mechanically aligning a TKR. A different alignment method known as kinematic alignment respects the natural bow legged or knock kneed alignment of the patient. It is hoped that kinematically aligning a knee replacement will improve how the knee feels to the patient and therefore improve their satisfaction.\n\nAnother potential factor affecting the outcomes of TKR is obtaining optimal soft tissue balance. The challenge with balancing a TKR is that traditional operative techniques rely on subjective feel of the knee stability during surgery. The balance or tension in the knee can however be objectively measured using specialized intraoperative pressure sensing devices.\n\nThe purpose of this study is to assess the impact of kinematically aligned TKR on the pressures measured by Verasense during total knee replacements. The study will also determine if differences in the pressure measured during TKR surgery impact patient outcomes after surgery.",[27],"2025-02-14",{"date":519,"type":32},"2025-02-17",{"date":521,"type":32},"2018-07-23",{"date":523,"type":23},"2026-09",{"name":525,"class":39},"Nova Scotia Health Authority",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":215,"maxAge":216,"enrollmentInfo":533,"targetDuration":4,"studyType":51,"phases":534,"briefSummary":535,"conditions":536,"keywords":537,"overallStatus":272,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":40},"100420093","phase-1-safety-and-tolerability-of-stromel-in-subjects-with-moderate-to-severe-osteoarthritis-of-the-knee-joint-100420093","NCT04750252","Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint","An Open Label Study to Evaluate Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint","Inclusion Criteria:\n\n1. Adults between the ages of 25-65 years\n2. Body Mass Index (BMI) less than 40 kg\u002Fm2\n3. Ambulatory and in good general health as described by vital signs (blood pressure 90\u002F60 mm Hg to 120\u002F80 mm Hg, pulse rate 60-100 beats per minute, temperature 97.2-99.1 °F) and normal blood chemistry.\n4. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain score of ≥ 11 (worst possible = 20) over the previous 7 days\n5. OA of the knee with Kellgren and Lawrence radiographic classification (Grade 2-4 inclusive) within the last 6 months\n6. Minimum score of 40 out of possible 100 on the VAS (Visual Analog Scale) for pain.\n7. Patients who have failed to adequately respond for at least 6 months to at least 2 OA therapies that include conservative, non-pharmacological therapy and simple analgesics (e.g., acetaminophen); nonsteroidal anti-inflammatory drugs (NSAIDS); avoidance of activities that cause joint pain; exercise; weight loss; physical therapy; and removal of excess fluid from the knee.\n8. Have suitable knee joint anatomy for intra-articular injection.\n9. For adults of reproductive potential: use of effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.\n\nExclusion Criteria:\n\n1. Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.\n2. Subject with an infection that requires parenteral antibiotic administration.\n3. Active infection or crystal disease in the index joint within 1 month of screening\n4. History of fracture in the index limb, joint instability, or history of acute dislocation within 12 months of screening, or fracture with sequelae at any time\n5. Intra-articular treatment of any joint with any of the following agents within 6 months of screening: Any corticosteroid preparation (investigational or marketed), sodium hyaluronate, any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection); investigational six months prior to enrollment.\n6. Presence of surgical hardware or other foreign body in the index joint\n7. Subjects who were administered with immunosuppressants such as cyclosporin A or azathioprine within 6 weeks before screening.\n8. Planned or anticipated surgery of the joint during the study period\n9. Allergies to anesthesia\n10. Subjects who tested positive for HIV, HCV, WNV, CMV, HBV, HTLV, ZIKA, syphilis, flu or COVID-19. Note: CMV is not a relevant communicable disease agent. A subject who tests positive or reactive for CMV is not necessarily ineligible. Physicians will determine donor eligibility for subjects with positive CMV test results.\n11. History of lipid disorders: lipedema, lipomatosis, or lipodystrophies.\n12. Active cancer, chemotherapy, or other malignancies in the last 6 months.\n13. Recent history of DVT or pulmonary embolism requiring anticoagulants or other medicines per the hematologist.\n14. Subject who participated in another clinical trial within 3 months before the screening visit\n15. Any illness which, in the Investigator's judgment, will interfere with the subject's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results.\n16. Subjects who are breastfeeding\n17. Subjects with uncontrolled arrhythmias\n18. Subjects with hemophilia; factor II, V, VII, X, or XII deficiencies; or Von Willebrand's disease.",{"count":22,"type":23},[353,354],"The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.",[27],[538],"Stem cell, MSC, autologous, adipose","2025-01-27",{"date":541,"type":32},"2025-01-29",{"date":543,"type":23},"2025-10-01",{"date":545,"type":23},"2027-08-31",{"name":547,"class":207},"Akan Biosciences, LLC",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":131,"sex":18,"minAge":103,"maxAge":556,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":559,"conditions":560,"keywords":562,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":40},"100565094","persistent-pain-in-pharmacologically-or-surgical-treated-osteoarthritis-role-of-mu-limpho-marker-100565094","NCT06637709","Persistent Pain in Pharmacologically or Surgical Treated Osteoarthritis: Role of Mu-Limpho Marker","Persistent Pain in Pharmacologically or Surgical Treated Osteoarthritis: the Role of the Mu-Lympho Marker As a Candidate Innovative Diagnostic Tool","MLM","Inclusion Criteria:\n\n* primary osteoarthritis with disabling pain, age older than 18 years at the time of surgery, capability tocommunicate with healthcare professionals and give valid informed consent, and a willingness to participate in a 24-month follow-up.\n\nExclusion Criteria:\n\n* (1) patients who underwent: surgical knee joint procedures; intra-articular knee injection in the last 3 months; (2) patients with: severe psychiatric disorder \\[excluding mild depression\\] or mental\u002Fcognitive impairment; a history \\[in the last 3 months\\] of fracture or trauma; (3) patients with a history in the last 6 months or currently suffering from: immunodeficiency diseases; connective tissue disease; infections; (4) pregnancy (5) patients ongoing opioids.","99 Years",{"count":558,"type":23},192,"The goal of this prospective observational study is to analyze the percentage of expression of B and NK cells expressing Mu opioid receptor on their surface, named Mu-Lympho-Marker (MLM), to measure pain progression in Osteoarthritis patients and its association with specific rehabilitation programs. In particular, we want to analyze the role of MLM as diagnostic biomarker of pain chronicization.\n\nThe main aims are:\n\n* to explore the relationship between Mu+ B and NK cells percentage and pain progression in OA patients, also investigating whether this characteristic is associated to particular outcome of pharmacological and\u002For surgery interventions and rehabilitation\n* to characterize Mu+ B and NK cells in terms of maturation states, activation\u002Finhibition and functional properties, as well as their ability to respond to Mu stimulation, in order to understand whether these cells can have a role in the pathogenesis of OA associated CP\n* to investigate the potential confounding effect of other biological and psychological elements in the relationship between the MLM and OA pain progression\n\nResearchers will compare two study groups:\n\n1. Experimental group: subjects suffering from symptomatic knee OA. 1S)surgical subgroup: OA patients from the experimental group requiring primary TKA due to the failure of conservative treatment, thus undergoing surgical intervention;\n2. Control group: subjects without any chronic pain, undergoing occupational health surveillance matched by age, sex and psychological profile with the experimental group patients Participants will be asked to do blood sample collections at specific time points to evaluate MLM stability over time and its modulation according to pharmacological\u002Fsurgical and rehabilitation interventions. Subjects in the control group will undergo 2 blood sample collections. Pain assessment will be performed at all scheduled time points to correlate pain severity with Mu expression in B and NK cells.",[561,27],"Chronic Pain",[563,564,565],"pain biomarkers","Mu opioid receptor","tailored therapy","2024-10-09",{"date":568,"type":32},"2024-10-15",{"date":570,"type":32},"2023-11-07",{"date":115,"type":23},{"name":573,"class":39},"IRCCS San Raffaele Roma",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":51,"phases":585,"briefSummary":586,"conditions":587,"keywords":592,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":343},"100380788","adipose-derived-biocellular-regenerative-therapy-for-osteoarthritis-100380788","NCT04238143","Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis","Adipose-Derived Biocellular Regenerative Therapy in Treatment of Osteoarthritis (OA) and Associated Connective Tissue Degeneration and Pain","GARM-MSK-ALD","Inclusion Criteria:\n\n* Documented osteoarthritic inflammatory and\u002For degenerative changes in the joint or connective tissues of the knee, hip, shoulder, Achilles tendon, Sacroiliac Joint, wrist\u002Fhand, foot\u002Fankle, or Plantar Fasciitis (PR);\n* No systemic disorders which, in opinion of principal investigator, would disqualify from safely being able to undergo the determined procedures;\n* Have the ability to understand and accept all items in Informed Consent Document;\n* Have adequate perivascular and extracellular matrix donor tissues available;\n* Mature enough to tolerate determined procedures and follow up instructions and complete post-treatment tracking responsibilities\n\nExclusion Criteria:\n\n* Systemic or psychological impairment which would preclude patient tolerance and understanding nature and extent of procedures and follow up tracking;\n* Known active cancer, chemotherapy, or radiation therapy;\n* Pregnancy;\n* Active infections which would increase risk of patient to undergo treatment;\n* High dose steroid users, or recipients of corticosteroids with a six month period before treatment date;\n* Medication or Opiate addition, or in active treatment for drug rehabilitation;\n* History of documented severe traumatic brain injuries;\n* In the opinion of the principal investigator\u002Fprovider, the patient's condition or medical issues which would not allow the individual to fully accomplish or complete the study requirements","90 Years",{"count":584,"type":23},100,[53],"Use of Biocellular and cellular approaches to treatment of Osteoarthritis (OA), musculoskeletal aging processes, pain, and degenerative changes are to be studied with minimally invasive protocols, and non-pharmaceutical means to relieve OA and its associated issues. Traditional surgical interventions have not yielded convincing long-term outcomes, including total joint replacement surgeries and medical management of the supportive structures.\n\nThis study is to use a person's own stem\u002Fstromal Cells (autologous) plus HD-PRP (important healing growth factors and signal molecules) in such cases of OA for long-term minimally invasive treatments. Baseline (existing) findings are documented, and thence tracked as to progress deemed to be result of the intervention.",[139,27,588,589,590,591],"Osteo Arthritis Shoulders","Osteoarthritis of Multiple Joints","Osteoarthritis, Hip","Osteoarthritis - Ankle\u002FFoot",[593,594,595,197],"Arthritis","Degenerative","Joint Disease","2024-09-30",{"date":598,"type":32},"2024-10-01",{"date":600,"type":32},"2020-01-10",{"date":602,"type":23},"2027-09-30",{"name":604,"class":207},"Healeon Medical Inc",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":240,"enrollmentInfo":612,"targetDuration":4,"studyType":51,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":40},"100561488","the-effect-of-body-mass-index-on-short-term-results-of-hto-100561488","NCT06590818","The Effect of Body Mass Index on Short-term Results of HTO","The Effect of Body Mass Index on Short-term Results of HTO for Treatment of OA With Varus Knee in Upper Egypt Population","Inclusion Criteria:\n\n* Meet the diagnostic criteria for knee osteoarthritis and only have one knee\n* No serious underlying medical disease\n* Conservative treatment is ineffective and there is a willingness for surgery\n* X-ray shows degeneration limited to the medial joint space (Ahlback grade ≥ grade II)\n* Knee flexion range of motion \\> 90°, varus deformity \\\u003C 15°, flexion contracture \\\u003C 5°.\n* Clinical examination shows intact anterior cruciate ligament and collateral ligament, tenderness point is limited to the medial joint space, and the lateral compartment and patellofemoral joint are intact.\n\nExclusion Criteria:\n\n* knee osteoarthritis caused by infection, blood-related or autoimmune diseases.\n* severe obesity (BMI\\>35 kg\u002Fm 2 ) or morbid obesity (obesity caused by diseases such as hypercortisolism and hypothyroidism, BMI≥30 kg\u002Fm 2 ).",{"count":613,"type":23},50,[53],"The knee joint plays a major role in weight transmission of the body in day-to-day activities. The biomechanics of the knee and malalignment in lower limb anatomy are major risk factors for chronic knee pain, leaving Total Knee Arthroplasty (TKA) as the best and most successful option for patients with end-stage osteoarthritis (OA)",[27,617],"Varus Knee","2024-09-06",{"date":620,"type":32},"2024-09-19",{"date":622,"type":32},"2024-07-10",{"date":624,"type":23},"2025-07-10",{"name":626,"class":207},"Egymedicalpedia",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":216,"enrollmentInfo":634,"targetDuration":4,"studyType":51,"phases":636,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":40},"100535290","efficacy-of-bioceramic-materials-for-bone-defects-repair-100535290","NCT06249906","Efficacy of Bioceramic Materials for Bone Defects Repair","Clinical Study of Bioceramic Materials in Bone Defect Repair","Inclusion Criteria:\n\n1. Patients who voluntarily take the test and sign the informed consent form;\n2. Patients aged 18-65 years old with no history of allergies;\n3. Patients able to communicate well with the investigator and follow the requirements of the entire trial.\n\nExclusion Criteria:\n\n1. Patients who refuse to sign the informed consent form to participate in the trial;\n2. Patients who are not in the age range of 18 to 65 years;\n3. Patients with diseases unsuitbale for the trial: history of allergies, severe cardiopulmonary disease, coagulation dysfunction, Alzheimer's disease, cerebral atrophy, acute phase or sequelae of cerebrovascular disease, cognitive impairment;\n4. Patients in the acute phase of local or systemic bacterial infections;\n5. Patients who cannot cooperate with the operation and evaluate the effect;\n6. Other conditions that are considered inappropriate by the investigator to participate in the study.",{"count":635,"type":23},10,[53],"The purpose of this study is to demonstrate the effect of bioceramic implants on the repair of human bone defects, and to explore the application of bioceramic materials in bone defects, bone implantation, and bone fusion. The surface microstructure of β-tricalcium phosphate bioceramic implants can be effectively controlled to guide the regeneration of bones, promote the restoration of bones, accelerate the speed of recovery, and improve bone quality, which is of great clinical and social significance.",[639,640,27,641,642,643],"Bone Lesion","Cartilage Degeneration","Bone Fracture","Bone Injury","Bone Loss","2024-03-08",{"date":646,"type":32},"2024-03-12",{"date":648,"type":32},"2024-02-20",{"date":650,"type":23},"2026-12-30",{"name":652,"class":39},"Nanjing First Hospital, Nanjing Medical University",{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":582,"enrollmentInfo":661,"targetDuration":4,"studyType":51,"phases":662,"briefSummary":663,"conditions":664,"keywords":666,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":343},"100523359","rfa-or-chemical-neurolysis-of-the-genicular-nerves-compared-to-conservative-treatment-for-knee-pain-caused-by-oa-100523359","NCT06094660","RFA or Chemical Neurolysis of the Genicular Nerves Compared to Conservative Treatment for Knee Pain Caused by OA","Patients With Knee Pain Caused by Osteoarthritis: Comparison of Conservative Medical Management With RadioFrequency Ablation or Chemical Neurolysis of the Genicular Nerves With Phenol","RADIOPHENOL","Inclusion Criteria:\n\n1. Adult patients of both sexes, \\>35 years who are not a candidate for TKA due to young age, old age, comorbidity or technical reasons.\n2. OKS \\\u003C 30 on a scale from 0 (severe function) to 48 points (satisfactory function).\n3. Continued pain in the target knee that is moderate to severe (defined as NRS ≥ 6 on an 11-point NRS scale) either constantly or with motion despite at least 3 months of conservative treatments. Conservative treatment can include: active physiotherapy, pharmacological treatment of pain (acetaminophen or NSAIDs) and intra-articular corticosteroid infiltration.\n4. Radiologic confirmation of arthritis for the target knee. Defined as the Kellgren Lawrence (KL) score of 2 or more on X-ray or MRI.\n\nExclusion Criteria:\n\n1. Patient with prior ablation of the genicular nerves, prior partial, resurfacing, or TKA of the target knee (residual hardware).\n2. Patient with a history of neurovascular injury or recent trauma of the lower extremities.\n3. Patient with chronic widespread pain.\n4. Polyneuropathy and\u002For radicular pain in the lower extremities.\n5. Patient is currently implanted with a neurostimulator.\n6. Local or systemic infection (bacteraemia).\n7. Uncontrolled immune suppression.\n8. Intra-articular injections (steroids, hyaluronic acid, platelet enriched plasma, stem cell, …) in the target knee within 90 days from randomisation.\n9. Arthroscopic debridement\u002Flavage into the target knee within 180 days from randomisation.\n10. BMI\\\u003C18,5 kg\u002Fm2 and patients with minimal subcutaneous tissue thickness that would not accommodate ablation with phenol or radio frequency (risk of skin burns).\n11. Allergies to products used during the procedure (lidocaine, phenol, contrast dye).\n12. Patients who have a planned TKA in the near future, defined as patients who already have agreed on a date for the TKA procedure.\n13. Patients with psychosocial problems as determined by the investigator.",{"count":558,"type":23},[53],"A randomised controlled triall (RCT) with three parallel arms comparing the functional outcome of chemical ablation with phenol and radiofrequency ablation (RFA) of the genicular nerves with conservative treatment in patients with chronic knee pain caused by osteoarthritis (OA).",[27,665],"Knee Pain Chronic",[269,667,668,669],"Thermal ablation","Phenol neurolysis","Genicular nerve","2023-12-04",{"date":672,"type":32},"2023-12-05",{"date":674,"type":32},"2023-11-27",{"date":676,"type":23},"2026-11-01",{"name":678,"class":39},"Dijklander Ziekenhuis"]